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Introduction: Thymic carcinoma is a rare and invasive mediastinal
neoplasm that often metastasizes. It constitutes a heterogeneous
group of tumors that displays different biologic behavior and prog-
nosis. The clinical prognostic factors and treatment of thymic
carcinoma are not yet standardized.
Methods: Thirty patients with thymic carcinoma have been treated
at Nagoya City University Hospital since 1983. The clinical and
pathologic data of these patients were retrospectively reviewed.
Thirteen cases were considered to be unresectable or inoperable and
received chemotherapy or chemoradiotherapy. Seventeen cases un-
derwent resection; total in 7 cases and subtotal in 10 cases. Postop-
erative irradiation was added as adjuvant therapy in the tolerable
cases. The most recent five cases received induction chemotherapy.
Results: In 17 of the 30 cases, the patients died. The survival
periods in the death cases were from 2.4 to 78.1 months (mean, 32.4
months; median, 21.0 months). The observation periods in the 13
live cases were 6.3 to 232 months (average follow-up, 64.6 months).
The 5-year survival rate was 47.5%, and median survival time
(MST) was 49.0 months. Cases that underwent total resection
showed significantly better prognosis than cases with subtotal re-
section (p 0.011) and inoperable cases (p 0.002). The cases that
underwent subtotal resection showed significantly better prognosis
than the inoperable cases (p 0.050). The cases with hematogenous
metastasis demonstrated significantly poorer prognosis (p  0.021),
but lymphogenous metastasis was not a significant predictor of poor
prognosis. Only resectability was a significant prognostic factor in
multivariate Cox regression analysis, and the hazard ratio was 5.123.
Conclusions: Resectability was the only prognostic factor in thymic
carcinoma. We suggest the importance of preoperative precise
evaluation to exclude unresectable Masaoka stage IVb disease and
expect preoperative chemotherapy or chemoradiotherapy to improve
the respectability.
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Thymic carcinoma is a rare and invasive mediastinal neo-plasm that often metastasizes. It constitutes a heteroge-
neous group of tumors that displays different biologic behav-
ior and prognosis. Chung et al. reported 305 patients with
thymic carcinoma compiled from a Medline search from
1966 to 2000.1 Kondo et al. reported 1320 patients with
thymic epithelial tumors who were treated in 115 institutes in
Japan from 1990 to 1994.2 Their report included 186 thymic
carcinomas. Other than these reports of the accumulation of
cases from multiple institutions, only limited numbers of pa-
tients have been analyzed. Some reports suggested that tumor
resectability, tumor stage, and tumor histology grading influ-
enced the outcome.3–5 Nevertheless, the clinicopathologic char-
acteristics are still unclear. We treated 30 patients with thymic
carcinoma from 1983 to 2006 at a single institution, and retro-
spectively reviewed their data to determine clinical prognostic
factors and appropriate staging classification.
PATIENTS AND METHODS
Thirty patients with thymic carcinoma have been
treated at Nagoya City University Hospital since 1983. The
clinical and pathologic data of these patients were retrospec-
tively reviewed. The study was approved by the Institutional
Review Board of Nagoya City University Hospital. Written
informed consent was obtained from all living patients and
the families of deceased patients There were 16 men and 14
women, with a mean age of 59 years (median, 59.5) and a
range between 33 and 84 years. Seventeen of 30 patients had
clinical symptoms: chest pain (n  9), facial or arm edema
(n 4), cough (n 2), hoarseness (n 1), and hemosputum
(n  1). No patients had concomitant paraneoplastic syn-
dromes such as myasthenia gravis or pure red cell aplasia.
Pretreatment evaluation of the tumor was done by physical
examination, chest radiography, chest computed tomography
(CT) scan and/or chest magnetic resonance imaging, abdom-
inal CT scan, or brain CT scan to evaluate whether the lesions
were resectable. In the six most recent cases, positron emis-
sion tomography was performed. Two patients underwent
surgical resection without pretreatment biopsy because the
tumor lesions were clinically diagnosed as noninvasive thy-
moma. For the other 28 tumors, pretreatment biopsy was
performed. Cases with World Health Organization (WHO)
classification type B3 thymoma (well-differentiated thymic
carcinoma) and carcinoid tumors were excluded from the
study. Treatment policy has changed transitionally. In the
inoperable cases, intravenous chemotherapy has been se-
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lected with or without irradiation therapy. The cases were
considered to be unresectable because of (1) apparent pleural
or pericardial dissemination, (2) massive invasion of the great
vessels or apparent invasion of the heart, or (3) hematogenous
or cervical lymphogenous metastasis. Adjuvant chemother-
apy has been considered an option for cases that underwent
total resection, and was selected routinely in cases with
subtotal resection and neuroendocrine carcinoma. Recently,
paclitaxel and carboplatin have been selected for non-small
cell carcinomas, and cisplatin-based regimens have been used
for neuroendocrine carcinoma. In the most recent five cases,
induction chemotherapy or chemoradiotherapy was per-
formed before the operation. Postoperative irradiation was
routinely added as adjuvant therapy in the tolerable cases that
did not receive preoperative radiation therapy. Preoperative
radiation therapy was limited to a dose of 40 Gy, and radical
radiation was fully performed at a dose of 60 Gy. To deter-
mine the relation between resectability and prognosis, clear
definitions of total resection and subtotal resection were
necessary. We defined total resection as macroscopically and
microscopically total resection of a tumor. For metastatic
lymph nodes, we defined total resection if the lymph nodes
with metastasis were located only in the anterior mediastinum
and were resected en-block with the thymus and the tumor.
We also regarded the cases with disseminations as subtotal
resection even if all nodules were resected macroscopically.
Because dissemination of thymic carcinoma was flat, it was
difficult to distinguish from whitish pleural thickness. I be-
lieve that many thoracic surgeons are anxious about the
resectability when dissemination nodules are removed mac-
roscopically during operation and even after the operation.
Only open biopsy or partial resection with residual large mass
was not included in subtotal resection, and we regarded those
cases as inoperable or unresectable.
Statistical analysis of survival was performed using the
Kaplan-Meier and univariable log-rank test. Multivariate Cox
regression analysis was performed. Statistical significance
was defined as p less than 0.05.
RESULTS
The most common histologic type was squamous cell
carcinoma (SqCC) (n  17). SqCC was diagnosed as well-
differentiated in five cases, moderate in five cases, moderate
to poor in three cases, and poor in four cases. Other histologic
types were neuroendocrine carcinoma (n  3; two small-cell
carcinoma and one large cell neuroendocrine carcinoma),
adenocarcinoma (n  2), poorly differentiated carcinoma
without adenocarcinoma or SqCC features (n  2), lympho-
epithelioma-like carcinoma (n  1), and two mixed subtypes
(adenoid cystic carcinoma and SqCC, mucoepidermoid car-
cinoma and SqCC). Three tumors were diagnosed as carci-
nomas without subclassification. Clinical and pathologic
staging were based on both the WHO classification6 and the
criteria described by Masaoka et al.7 In the WHO classifica-
tion, 2 cases were diagnosed as stage II disease, 14 cases were
stage III disease, and 14 cases were stage IV disease. In the
Masaoka classification, 2 cases were diagnosed as stage II
disease, 13 cases were stage III, 7 cases were stage IVa, and
8 cases were stage IVb disease.
Seventeen of 30 cases died of cancer itself or from
complications from cancer and its related treatment. The
survival periods in the death cases were from 2.4 to 78.1
months (mean, 32.4 months; median, 21.0 months). The
observation periods in the 13 live cases were 6.3 to 232
months (average follow-up, 64.6 months). Five-year survival
rate was 47.5%, and median survival time (MST) was 49.0
months (Figure 1).
Clinicopathologic factors and prognosis are reported in
Table 1. Gender and WHO T factor (primary tumor factor)
did not influence prognosis statistically. N factor (regional
lymph nodal factor) was also not a significant prognostic
factor, although all five cases with lymphogenous metastasis
died and had low 5-year survival rate (33.8%) and MST (40.0
months). M factor (distant metastasis factor) was also analyzed.
In the group with hematogenous metastasis, all four cases died
and no case experienced long survival with low MST (15.3
months). In the group without hematogenous metastasis, 13
cases died, and the 5-year survival rate was 58.3% and the MST
was 69.7 months. The cases with hematogenous metastasis
showed significantly poorer prognosis (p  0.021) than those
without hematogenous metastasis.
In stage classification, we have tried to classify in
WHO (Figure 2A) and Masaoka stages (Figure 3A). In WHO
classification, two cases of stage II survived without disease.
Six of 14 cases with stage III disease died and their 5-year
survival rate was 57.9% and their MST was 78.1 months.
Eleven of 14 cases with stage IV disease died and their 5-year
survival rate was 37.5% and their MST was 47.0 months.
Prognosis in the cases with stage II or III was better than in
the cases with stage IV disease, but it was not significant (p
0.064) (Figure 2B).
In the Masaoka classification, two cases of stage II
survived without disease. Five of 13 cases with stage III
disease died, and the 5-year survival rate was 53.8%. MST
was not predicted. Four of seven cases with stage IVa disease
died and their 5-year survival rate was 64.3% and their MSTwas
68.0 months. All eight cases with stage IVb disease died and
their 5-year survival rate was 25.0% and their MST was 15.3
months. There were no significant differences in prognosis
among stage II  III, IVa, and IVb (p  0.115) (Figure 3B).
FIGURE 1. Overall survival of 30 cases. Five-year survival
rate was 47.5% and median survival time (MST) was 49.0
months.
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Histologic classification of thymic carcinoma has been
suggested by Suster and Rosai.3 In this study, 7 cases were
diagnosed in the low risk group and 20 cases were in the
high-risk group. Three of seven cases in the low risk group
died and the 5-year survival rate was 68.0%. Eleven of 20
cases in the high-risk group died and the 5-year survival rate
was 69.7% and the MST was 50.5 months. There was no
significant difference in the survival of these groups.
Resectability and prognosis were assessed in our study
(Figure 4). We defined total and subtotal resection clearly, as
stated in the materials and methods. Total resection was
performed in six cases, and all six cases survived over 5
years. Subtotal resection (subtotal resection) was performed
in 10 cases. Six of the 10 cases with subtotal resection died
and their 5-year survival rate was 56.0% and their MST was
69.7 months. In the inoperable cases, 10 of 13 cases died and
their 5-year survival rate was 14.1% and their MST was 23.0
months. The cases that underwent total resection showed
significantly better prognosis than the cases with subtotal
resection (p  0.011) and the inoperable cases (p  0.002).
In addition, the cases that underwent subtotal resection
showed significantly better prognosis than the inoperable
cases (p  0.050).
Multivariate Cox regression analysis was performed for
WHO M factor (hematogenous metastasis), WHO stage,
Masaoka stage, and resectability (total resection or subtotal
resection or inoperable). Only resectability was a significant
prognostic factor and the hazard ratio was 5.123 (Table 2).
DISCUSSION
We determined that resectability was the only prognos-
tic factor in thymic carcinoma in this study. It has been
reported that total resection of thymic carcinoma significantly
TABLE 1. Clinocopathological Factors and Prognosis









Male 8/16 46.2 49.0 p  0.889
Female 9/14 49.2 47.0
WHO classification
T2 1/3 100 78.0 p  0.359
T3 9/17 42.8 33.8
T4 7/10 42.0 49.0
WHO classification
N0 12/25 49.0 49.1 p  0.302
N1  2 5/5 33.8 40.0
WHO classification
M0 13/26 69.7 58.3 p  0.021
M1 4/4 15.3 0
WHO stage
II 0/2 100 N/A II  III vs. IV
p  0.064
III 6/14 57.9 78.0
IV 11/14 37.5 47.0
Masaoka stage
II 0/2 100 N/A II  III, IVa and
IVb p  0.115
III 5/13 53.8 N/A
IVa 4/7 64.3 68.0
IVb 8/8 25.0 15.3
Histology
High risk 11/20 69.7 50.5 p  0.281
Low risk 3/7 68.0 64.3
(Unknown) (3/3)
Resectability p  0.002
Total resection 1/7 100 N/A TR vs. SR:
p  0.011
Subtotal resection 6/10 56.0 69.7 SR vs. IO:
p  0.050
Inoperable 10/13 14.1 23.0 TR vs. IO:
p  0.002
N/A, not available; TR, total resection; SR, subtotal resection; IO, inoperable.
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increased survival rate.2,4 In this study, many variations in
treatment procedure were present, although most cases that
underwent total resection or subtotal resection received irra-
diation therapy (15/17, 88%). We think the prognosis of those
cases that underwent total or subtotal resection depended on
the combination effect of resection and radiation therapy.
Kondo et al. reported better prognosis in cases with total
resection than in cases with subtotal resection or inoperable
cases.2 Tseng et al. also reported better prognosis in cases
with complete resection and poor prognosis in cases with
tumor invasion of the great vessels.4 In this study, we also
demonstrated better prognosis in the cases with total resec-
tion. In addition, the cases with subtotal resection demon-
strated better prognosis than the inoperable cases. We spec-
ulated that the difference between Kondo’s report and our
study depended on the definition of total resection and sub-
total resection. Kondo et al. defined total resection as a
condition in which no tumor remained macroscopically. In
our study there were two cases with small number of dissem-
ination nodules (Masaoka IVa stage) and they showed better
prognosis. Probably such cases that underwent macroscopi-
cally total resection were included in the total resection group
in Kondo’s study. We included such cases with dissemination
in the group with subtotal resection even if all nodules were
resected macroscopically, because dissemination nodules of thy-
mic carcinoma was flat and it was difficult to distinguish from
whitish pleural thickness. I believe many thoracic surgeons are
not confident of the resectability, whether total resection is
performed or not during operation and even after the operation.
From these experiences we have defined the macroscopic total
resection of pleural dissemination as subtotal resection. In addi-
tion, radiation therapy was performed for all cases with subtotal
resection in our study. This effect may have contributed to
improve prognosis of the cases with subtotal resection.
Although resectability was the only prognostic factor
with a high hazard ratio (5.123), it is not an original prog-
nostic factor. Whether resection is performed or not is eval-
uated by preoperative assessment and perioperative findings
and these assessments are important. We think that righteous-
ness of these assessments which we have performed was
demonstrated. We cannot improve the prognosis of inopera-
FIGURE 2. WHO stage classification and prognosis. A,
Prognosis in three stages (II, III, and IV) were compared. B,
Stages II and III were joined.
FIGURE 3. Masaoka stage classification and prognosis. A,
Prognosis in four stages (II, III, IVa, and IVb) were compared.
B, Stages II and III were joined.
FIGURE 4. Resectability and prognosis. The cases that un-
derwent total resection demonstrated significantly better
prognosis than the cases with subtotal resection (p  0.011)
and the inoperable cases (p  0.002). The cases that under-
went subtotal resection also demonstrated significantly bet-
ter prognosis than the inoperable cases (p  0.050).
TABLE 2. Multivariate Cox Regression Analysis
Factors Significance (p) Hazard Ratio
WHO classification M factor 0.604 1.548
WHO stage 0.630 1.546
Masaoka stage 0.205 2.030
Resectability 0.003 5.123
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ble cases even if they undergo subtotal resection. There was
a poor prognosis for the cases with Masaoka Stage IVb
disease that underwent subtotal resection. Two cases with
Masaoka stage IVb disease died 2.4 and 13.3 months after
subtotal resection. Therefore, we do not recommend partial
resection of unresectable tumors (inoperable cases) as de-
bulking surgery. It is necessary to determine the real opera-
tive indication to improve the operative result. In this study,
we could not strictly determine the inoperable indications.
Nevertheless, we consider that Masaoka stage IVb disease
should be excluded from the operative indication.
In addition, to improve the resectability, we expect
preoperative chemotherapy. Chemotherapy has been reported
to be effective in thymic carcinoma.8,9 Recently, the effect of
doublet chemotherapy consisting of carboplatin and pacli-
taxel has been reported.10–12 We performed preoperative
chemotherapy or chemoradiotherapy in our most recent four
cases. No cases showed any complications of preoperative
adjuvant therapy. It was not possible to evaluate whether the
preoperative chemotherapy or chemoradiotherapy had a pos-
itive effect on survival.
Because a newWHO classification of malignant thymic
epithelial tumor was published in 2004,6 we adapted 30 cases
with thymic carcinoma to the WHO classification and the
Masaoka classification. There have been no thymic carci-
noma specific stage classifications. We have so far used the
Masaoka classification that was created for thymoma.7 In this
study, we compared the WHO classification and the Masaoka
classification. Thymic carcinoma is usually diagnosed with
the advanced stages. In our study, most cases (28 of 30 cases,
93%) were diagnosed with WHO stage III or IV. If we use the
WHO classification, the distribution of cases trends toward
advanced stages. On the other hand, Masaoka stage classifi-
cation divides stage IV into stages IVa and IVb, and the
distribution is better balanced. In the relationship between
stage and prognosis, both the WHO and Masaoka classifica-
tions did not demonstrate statistical significance in prognosis
by single and multivariate analysis. More accumulation of
cases will be necessary to evaluate the relationship between
stage and prognosis. New original stage classification for
only thymic carcinoma may be necessary.
It is necessary to add the limitations of our study, for
example, it was retrospective and it covered for long periods. In
addition, many different treatments have been given for cases.
In conclusion, resectability was the only prognostic
factor in thymic carcinoma. To increase the resectability, we
suggest the importance of precise preoperative evaluation to
exclude unresectable Masaoka stage IVb disease and expect
preoperative chemotherapy or chemoradiotherapy to improve
the respectability.
REFERENCES
1. Chung DA. Thymic carcinoma—analysis of nineteen clinicopathologi-
cal studies. Thorac Cardiov Surg 2000;48:114–119.
2. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical
study of 1,320 patients from Japan. Ann Thorac Surg 2003;76:878–884.
3. Suster S, Rosai J. Thymic carcinoma—a clinicopathologic study of 60
patients. Cancer 1991;67:1025–1032.
4. Tseng YL, Wang ST, Wu MH, et al. Thymic carcinoma: involvement of
great vessels indicates poor prognosis. Ann Thorac Surg 2003;76:1041–
1045.
5. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic
carcinoma: a retrospective analysis of 40 cases. Cancer 2002;94:3115–
3119.
6. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health
Organization classification of tumours. Pathology and genetics of tu-
mours of the lung, pleura, thymus and heart. Lyon: International agency
for research on cancer press; 2004:146–151.
7. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymo-
mas with special reference to their clinical stages. Cancer 1981;48:
2485–2492.
8. Weide LG, Ulbright TM, Loehrer PJ Sr, et al. Thymic carcinoma.
A distinct clinical entity responsive to chemotherapy. Cancer 1993;71:
1219–1223.
9. Lucchi M, Mussi A, Basolo F, et al. The multimodality treatment of
thymic carcinoma. Eur J Cardiothorac Surg 2001;19:566–569.
10. Greene MA, Malias MA. Aggressive multimodality treatment of inva-
sive thymic carcinoma. J Thorac Cardiovasc Surg 2003;125:434–436.
11. Komatsu Y, Koizumi T, Tanabe T, et al. Salvage chemotherapy with
carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma-three
cases. Anticancer Res 2006;26:4851–4855.
12. Maruyama R, Suemitsu R, Okamoto T, et al. Persistent and aggressive
treatment for thymic carcinoma. Results of a single-institute experience
with 25 patients. Oncology 2006;70:325–329.
Journal of Thoracic Oncology • Volume 3, Number 3, March 2008 Thymic Carcinoma
Copyright © 2008 by the International Association for the Study of Lung Cancer 269
